MA52591A - Échafaudage peptidique autoassemblé - Google Patents

Échafaudage peptidique autoassemblé

Info

Publication number
MA52591A
MA52591A MA052591A MA52591A MA52591A MA 52591 A MA52591 A MA 52591A MA 052591 A MA052591 A MA 052591A MA 52591 A MA52591 A MA 52591A MA 52591 A MA52591 A MA 52591A
Authority
MA
Morocco
Prior art keywords
peptidic
scaffolding
assembled
self
peptidic scaffolding
Prior art date
Application number
MA052591A
Other languages
English (en)
Inventor
Keith Douglas Miller
Original Assignee
Hexamer Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hexamer Therapeutics Inc filed Critical Hexamer Therapeutics Inc
Publication of MA52591A publication Critical patent/MA52591A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA052591A 2018-07-12 2019-07-12 Échafaudage peptidique autoassemblé MA52591A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862697132P 2018-07-12 2018-07-12

Publications (1)

Publication Number Publication Date
MA52591A true MA52591A (fr) 2021-06-02

Family

ID=69142622

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052591A MA52591A (fr) 2018-07-12 2019-07-12 Échafaudage peptidique autoassemblé

Country Status (12)

Country Link
US (2) US12458692B2 (fr)
EP (2) EP4218928A3 (fr)
JP (2) JP2021531337A (fr)
KR (1) KR20210065086A (fr)
CN (1) CN112512552B (fr)
AU (2) AU2019300038C1 (fr)
BR (1) BR112021000455A2 (fr)
CA (1) CA3105706A1 (fr)
MA (1) MA52591A (fr)
MX (1) MX2021000444A (fr)
WO (1) WO2020014609A2 (fr)
ZA (1) ZA202100952B (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220062080A (ko) * 2019-09-12 2022-05-13 헥사머 테라퓨틱스, 인코포레이티드 전립선암 치료를 위한 면역요법
WO2021226026A2 (fr) * 2020-05-04 2021-11-11 Hexamer Therapeutics, Inc. Vaccins contre des agents pathogènes viraux

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432260A (en) * 1991-05-03 1995-07-11 Washington University High affinity mannose receptor ligands
GB9202219D0 (en) 1992-02-03 1992-03-18 Connaught Lab A synthetic heamophilus influenzae conjugate vaccine
CN1414976A (zh) 1999-12-08 2003-04-30 明德塞特生物制药(美国)公司 作为免疫原的嵌合肽及其抗体,以及利用嵌合肽或抗体进行免疫的方法
CA2638912A1 (fr) * 2006-02-20 2007-08-30 Phylogica Limited Procede de construction et de criblage de bibliotheques de structures peptidiques
WO2009030780A2 (fr) 2007-09-07 2009-03-12 Complix Nv Echafaudage protéique non naturel constitué de trois peptides associés de manière non covalente
EP2537937A3 (fr) * 2008-04-29 2013-04-10 Monsanto Technology LLC Gènes et utilisation pour l'amélioration de plantes
WO2013040142A2 (fr) 2011-09-16 2013-03-21 Iogenetics, Llc Procédés bio-informatiques de détermination de liaisons peptidiques
AU2011358840B2 (en) 2011-02-11 2017-05-04 TauRx Therapeutics Management Ltd Phenothiazine diaminium salts and their use
WO2013009971A1 (fr) 2011-07-12 2013-01-17 E. I. Du Pont De Nemours And Company Procédé de détection et de criblage et matériaux utiles dans l'exécution de celui-ci
WO2014126828A1 (fr) 2013-02-15 2014-08-21 Merck Sharp & Dohme Corp. Nouveaux peptides à ph commutable pour une insertion dans une membrane et une formation de pores
AU2014321161B2 (en) 2013-09-16 2019-04-04 The University Of Queensland Silica micro- and nano-capsules and methods for making them
US10111948B2 (en) * 2014-04-25 2018-10-30 Tria Bioscience Corp. Synthetic hapten carrier compositions and methods
US11725041B2 (en) * 2016-08-11 2023-08-15 The Council Of The Queensland Institute Of Medical Research Immune-modulating compounds

Also Published As

Publication number Publication date
CA3105706A1 (fr) 2020-01-16
JP2021531337A (ja) 2021-11-18
CN112512552A (zh) 2021-03-16
MX2021000444A (es) 2021-05-27
KR20210065086A (ko) 2021-06-03
WO2020014609A4 (fr) 2020-04-16
WO2020014609A3 (fr) 2020-02-20
WO2020014609A2 (fr) 2020-01-16
EP4218928A2 (fr) 2023-08-02
BR112021000455A2 (pt) 2021-04-06
EP3826661A2 (fr) 2021-06-02
US20210268105A1 (en) 2021-09-02
AU2019300038A1 (en) 2021-02-04
AU2023202175A1 (en) 2023-05-04
US20260061049A1 (en) 2026-03-05
AU2019300038C1 (en) 2024-01-04
JP2024036461A (ja) 2024-03-15
EP4218928A3 (fr) 2023-12-13
EP3826661A4 (fr) 2022-08-31
ZA202100952B (en) 2023-10-25
US12458692B2 (en) 2025-11-04
CN112512552B (zh) 2024-10-22
AU2019300038B2 (en) 2023-01-12

Similar Documents

Publication Publication Date Title
EP3890716A4 (fr) Polythérapies
EP3846674C0 (fr) Spéculum vaginal
EP3555124C0 (fr) Tcr nyeso
PL3649151T3 (pl) Białka rusztowania
EP3849534A4 (fr) Polythérapies
DK4177504T3 (da) Forbindelse
EP3752740C0 (fr) Structures d'assemblage
EP3746081A4 (fr) Nouvelles utilisations
EP3781060A4 (fr) Cryosonde
EP3689999A4 (fr) Pulvérisateur
EP3784463A4 (fr) Fluorosulfones
IL283682A (en) Linkers
EP3872558A4 (fr) Optoisolateur
EP3805381A4 (fr) Phytase mutée
EP3810860C0 (fr) Coupleur
EP3745904C0 (fr) Poignée de bâton
EP3918156A4 (fr) Tentes
EP3878374A4 (fr) Dispositif d'occlusion
EP3554717C0 (fr) Appareil de pulvérisation
EP3721129A4 (fr) Cryosphère
EP3898177C0 (fr) Configuration de moule
EP3636850C0 (fr) Pergola
EP3844177A4 (fr) Polythérapies
DK3587968T3 (da) Fluidsystem
MA52591A (fr) Échafaudage peptidique autoassemblé